| A genome-wide association study of Dupuytren disease reveals 17 additional variants implicated in fibrosis M Ng, D Thakkar, L Southam, P Werker, R Ophoff, K Becker, M Nothnagel, ... The American Journal of Human Genetics 101 (3), 417-427, 2017 | 112 | 2017 |
| The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal … CEZ Chan, SGK Seah, DH Chye, S Massey, M Torres, APC Lim, ... PLoS One 16 (6), e0253487, 2021 | 91 | 2021 |
| Considerations for treatment duration in responders to immune checkpoint inhibitors TU Marron, AE Ryan, SM Reddy, S Kaczanowska, RH Younis, D Thakkar, ... Journal for immunotherapy of cancer 9 (3), 2021 | 84 | 2021 |
| The sensitization of glioma cells to cisplatin and tamoxifen by the use of catechin A Shervington, V Pawar, S Menon, D Thakkar, R Patel Molecular biology reports 36, 1181-1186, 2009 | 50 | 2009 |
| Gene expression profiles of changes underlying different-sized human rotator cuff tendon tears S Chaudhury, Z Xia, D Thakkar, O Hakimi, AJ Carr Journal of Shoulder and Elbow Surgery 25 (10), 1561-1570, 2016 | 48 | 2016 |
| Distribution and expression of type VI collagen and elastic fibers in human rotator cuff tendon tears D Thakkar, TM Grant, O Hakimi, AJ Carr Connective tissue research 55 (5-6), 397-402, 2014 | 37 | 2014 |
| Rationally targeted anti-VISTA antibody that blockades the C-C’loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit … D Thakkar, S Paliwal, B Dharmadhikari, S Guan, L Liu, S Kar, NK Tulsian, ... Journal for Immunotherapy of Cancer 10 (2), 2022 | 31 | 2022 |
| Can hsp90α-targeted siRNA combined with TMZ be a future therapy for glioma? N Cruickshanks, L Shervington, R Patel, C Munje, D Thakkar, ... Cancer Investigation 28 (6), 608-614, 2010 | 26 | 2010 |
| HMBD004, a novel anti-CD47xCD33 bispecific antibody displays potent anti-tumor effects in pre-clinical models of AML J Boyd-Kirkup, D Thakkar, P Brauer, J Zhou, WJ Chng, PJ Ingram Blood 130, 1378, 2017 | 24 | 2017 |
| Ascorbic acid is essential for significant collagen deposition by human tenocytes in vitro O Hakimi, R Poulsen, D Thakkar, C Yapp, A Carr | 20 | 2014 |
| 10D1F, an anti-HER3 antibody that uniquely blocks the receptor heterodimerization interface, potently inhibits tumor growth across a broad panel of tumor models D Thakkar, V Sancenon, MM Taguiam, S Guan, Z Wu, E Ng, ... Molecular Cancer Therapeutics 19 (2), 490-501, 2020 | 13 | 2020 |
| Proteomic studies coupled with RNAi methodologies can shed further light on the downstream effects of telomerase in glioma D Thakkar, L Shervington, A Shervington Cancer Investigation 29 (2), 113-122, 2011 | 8 | 2011 |
| HMBD002, a novel neutralizing antibody targeting a specific epitope on the co-inhibitory immune checkpoint receptor VISTA, displays potent anti-tumor effects in pre-clinical models PJ Ingram, D Thakkar, JD Boyd-Kirkup Cancer Research 77 (13_Supplement), 587-587, 2017 | 7 | 2017 |
| Vista antigen-binding molecules JD Boyd-Kirkup, P Ingram, D Thakkar, Z Wu, K Paszkiewicz, V Sancenon, ... US Patent 10,633,456, 2020 | 6 | 2020 |
| HMBD-002 is a novel, neutralizing, anti-VISTA antibody exhibiting strong preclinical efficacy and safety, being developed as a monotherapy and in combination with pembrolizumab. L DiMascio, D Thakkar, N Gandhi, S Guan, EK Rowinsky, P Ingram, ... Journal of Clinical Oncology 39 (15_suppl), e14569-e14569, 2021 | 5 | 2021 |
| Integrative immune profiling of syngeneic tumor models provides predictive immune signatures for treatment response with HMBD002, a novel anti-VISTA neutralizing antibody JD Boyd-Kirkup, D Thakkar, K Paszkiewicz, PJ Ingram Cancer Research 78 (13_Supplement), 1729-1729, 2018 | 5 | 2018 |
| Vista antigen-binding molecules JD Boyd-Kirkup, P Ingram, D Thakkar, Z Wu, K Paszkiewicz, V Sancenon, ... US Patent App. 16/180,949, 2019 | 4 | 2019 |
| Her3 antigen-binding molecules JD Boyd-Kirkup, S Guan, P Ingram, K Paszkiewicz, V Sancenon, ... US Patent App. 16/170,370, 2019 | 4 | 2019 |
| Treatment and prevention of cancer using HER3 antigen-binding molecules JD Boyd-Kirkup, S Guan, P Ingram, K Paszkiewicz, V Sancenon, ... US Patent 11,208,498, 2021 | 3 | 2021 |
| Abstract P197: An anti-HER3 antibody, HMBD-001, that uniquely binds to and blocks the HER3 heterodimerization interface, shows superior tumor growth inhibition in biomarker … D Thakkar, S Paliwal, S Kar, N Gandhi, K Paszkiewicz, P Ingram, ... Molecular Cancer Therapeutics 20 (12_Supplement), P197-P197, 2021 | 3 | 2021 |
